Nucleix will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck® Lung Atlas, at the American Association for Cancer Research (AACR) Annual Event in Orlando, April 14-19.
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)-- Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck® Lung Atlas, at the American Association for Cancer Research (AACR) Annual Event in Orlando, April 14-19. The proprietary Lung Atlas was constructed and developed as part of a multi-institutional effort to map epigenetic and genomic changes associated with early-stage lung cancer, particularly stage I disease.
Presentations at AACR include:
-
Session date and time: April 17 at 1:30pm ET
-
Session date and time: April 18 at 1:30pm ET
“When lung cancer is detected early, it is more likely that patients will survive the disease,” said Chris Hibberd, CEO, Nucleix. “Currently though, most patients are diagnosed with late-stage cancer, even though research has shown that five-year survival rates are up to 10 times greater when lung cancer is detected early.i Results demonstrate the strength of Nucleix’s Lung EpiCheck assay and our differentiated approach for the discovery and identification of novel biomarkers for non-invasive lung cancer screening. We are leveraging these findings to advance a new generation of Lung EpiCheck, which incorporates novel markers from the Lung Atlas and is optimized to detect minute cancer epigenetic signals with greater sensitivity. The next step is well underway as we evaluate the new assay in the Sightline Trial, a 5,000 patient multicenter study in high-risk current and former smokers.”
Currently there are limited options for early lung cancer detection and only 10% of the nearly 15 million high-risk smokers recommended to receive low-dose CT imaging adhere to current guidelines.ii The Lung Atlas will aid in Nucleix’s development of the next generation of clinical assays. Nucleix’s Lung EpiCheck analyzes changes in multiple methylation markers to screen for lung cancer using a non-invasive blood sample, with a focus on testing individuals who are at high-risk based on smoking history. Lung EpiCheck has been optimized to focus on sensitivity, so that physicians have a better chance of early detection and patients have a better chance of successful treatment.
Learn more about Nucleix’s Lung EpiCheck.
About Nucleix
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS and PCR-based technologies, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® delivers highly accurate and sensitive results, while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck® franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals, while evaluating additional tests for other high-risk diseases. For more information, please visit: https://www.nucleix.com.
i American Lung Association. Lung Cancer Fact Sheet. 2020; https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet
ii U.S. Preventive Services Task Force. Lung Cancer: Screening. 2021; https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005579/en/
Source: Nucleix
View this news release online at:
http://www.businesswire.com/news/home/20230413005579/en
